{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:18:15Z","timestamp":1787797095763,"version":"build-2784847793"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-05036-8","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:40:48Z","timestamp":1781768448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exacerbation of myasthenia gravis after zoledronic acid and denosumab: a novel clinical observation with therapeutic implications"],"prefix":"10.1186","volume":"26","author":[{"given":"Stefania","family":"Canneva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"De Giovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicita","family":"Pagella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Trompetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Grandis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"5036_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019. https:\/\/doi.org\/10.1038\/s41572-019-0079-y.","journal-title":"Nat Rev Dis Primers"},{"key":"5036_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07097-2","author":"CJ Lin","year":"2024","unstructured":"Lin CJ, Lee YS, Yeh JH, Liu SJ, Lin KY. The association between myasthenia gravis and risk of fracture: a systematic review and meta-analysis. Osteoporos Int. 2024. https:\/\/doi.org\/10.1007\/s00198-024-07097-2.","journal-title":"Osteoporos Int"},{"key":"5036_CR3","doi-asserted-by":"publisher","unstructured":"V Oostwaard M. Osteoporosis and the nature of fragility fracture: an overview. In: Hertz K, Santy-Tomlinson J, editors. Fragility fracture nursing: holistic care and management of the orthogeriatric patient. Springer; 2018. https:\/\/doi.org\/10.1007\/978-3-319-76681-2.","DOI":"10.1007\/978-3-319-76681-2"},{"key":"5036_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/93.8.560","author":"SL Palin","year":"2000","unstructured":"Palin SL, Singh BM. Primary hyperthyroidism due to a parathyroid adenoma with subsequent myasthenia gravis. QJM. 2000. https:\/\/doi.org\/10.1093\/qjmed\/93.8.560.","journal-title":"QJM"},{"key":"5036_CR5","doi-asserted-by":"publisher","DOI":"10.4103\/0022-3859.37525","author":"V Raja","year":"2007","unstructured":"Raja V, Sandanshiv P, Neugebauer M. Risedronate induced transient ocular myasthenia. J Postgrad Med. 2007. https:\/\/doi.org\/10.4103\/0022-3859.37525.","journal-title":"J Postgrad Med"},{"key":"5036_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2768-4","author":"S Kesikburun","year":"2014","unstructured":"Kesikburun S, G\u00fczelk\u00fc\u00e7\u00fck U, Alay S, Yavuz F, Tan AK. Exacerbation of myasthenia gravis by alendronate. Osteoporos Int. 2014. https:\/\/doi.org\/10.1007\/s00198-014-2768-4.","journal-title":"Osteoporos Int"},{"key":"5036_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s004150170254","volume":"248","author":"G Smith","year":"2001","unstructured":"Smith G, Stevens D, Fuller G. Myasthenia gravis, corticosteroids and osteoporosis prophylaxis. J Neurol. 2001;248:151. https:\/\/doi.org\/10.1007\/s004150170254.","journal-title":"J Neurol"},{"issue":"5","key":"5036_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1034\/j.1600-0404.2001.103005320.x","volume":"103","author":"SJ Lewis","year":"2001","unstructured":"Lewis SJ, Smith PE. Osteoporosis prevention in myasthenia gravis: a reminder. Acta Neurol Scand. 2001;103(5):320\u20132. https:\/\/doi.org\/10.1034\/j.1600-0404.2001.103005320.x. 11328209.","journal-title":"Acta Neurol Scand"},{"key":"5036_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-012-1970-5","author":"S Pouwels","year":"2013","unstructured":"Pouwels S, de Boer A, Javaid MK, Hilton-Jones D, Verschuuren J, Cooper C, et al. Fracture rate in patients with myasthenia gravis: the general practice research database. Osteoporos Int. 2013. https:\/\/doi.org\/10.1007\/s00198-012-1970-5.","journal-title":"Osteoporos Int"},{"key":"5036_CR10","doi-asserted-by":"publisher","first-page":"123017","DOI":"10.1016\/j.jns.2024.123017","volume":"460","author":"S Konno","year":"2024","unstructured":"Konno S, Uchi T, Kihara H, Sugimoto H. Ten-year fracture risk in Japanese patients with myasthenia gravis: a comprehensive assessment using the fracture risk assessment tool. J Neurol Sci. 2024;460:123017. https:\/\/doi.org\/10.1016\/j.jns.2024.123017.","journal-title":"J Neurol Sci"},{"issue":"3","key":"5036_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2174\/1574886311666160426141647","volume":"11","author":"U Kaur","year":"2016","unstructured":"Kaur U, Chakrabarti SS, Gambhir IS. Zoledronate induced hypocalcemia and hypophosphatemia in osteoporosis: a cause of concern. Curr Drug Saf. 2016;11(3):267\u20139. https:\/\/doi.org\/10.2174\/1574886311666160426141647.","journal-title":"Curr Drug Saf"},{"key":"5036_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00198-023-06926-0","volume":"35","author":"A Sp\u00e5ngeus","year":"2024","unstructured":"Sp\u00e5ngeus A, Rydetun J, Woisetschl\u00e4ger M. Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection. Osteoporos Int. 2024;35:173\u201380. https:\/\/doi.org\/10.1007\/s00198-023-06926-0.","journal-title":"Osteoporos Int"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-05036-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05036-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-05036-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:46:30Z","timestamp":1787795190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-05036-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5036"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-05036-8","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The report was conducted in accordance with the Declaration of Helsinki and approved by the Territorial Ethics Committee of Liguria (CET Liguria: approval no.384\/2024-DB id 14133).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written and signed informed consent was obtained from the patient for the publication of this case report.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"545"}}